A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer.

abstract：:Mesothelioma is an incurable cancer for which effective therapies are required. Aberrant MET expression is prevalent in mesothelioma, although targeting using small molecule-based therapeutics has proven disappointing. Chimeric antigen receptors (CARs) couple the HLA-independent binding of a cell surface target to the...

journal_title：Oncoimmunology

authors： Thayaparan T,Petrovic RM,Achkova DY,Zabinski T,Davies DM,Klampatsa A,Parente-Pereira AC,Whilding LM,van der Stegen SJ,Woodman N,Sheaff M,Cochran JR,Spicer JF,Maher J

更新日期：2017-08-14 00:00:00

abstract：:Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

journal_title：Oncoimmunology

authors： Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

更新日期：2017-02-21 00:00:00

abstract：:Alkylating chemotherapy exerts both antineoplastic and immunostimulatory effects. However, in addition to depleting regulatory T cells (Treg), alkylating agents also mediate a long lasting antiproliferative effect on responder lymphocytes. Our recent findings indicate that this antiproliferative effect profoundly impa...

journal_title：Oncoimmunology

authors： Litterman AJ,Dudek AZ,Largaespada DA

更新日期：2013-10-01 00:00:00

abstract：:We have recently described two types of Langerhans cells (LCs), which develop via separate pathways in steady-state conditions and during inflammation. Here, we propose that these two types of LCs differ in their requirement for transforming growth factor β1 (TGFβ1), and we discuss how TGFβ1 impacts on the development...

journal_title：Oncoimmunology

authors： Seré K,Felker P,Hieronymus T,Zenke M

更新日期：2013-03-01 00:00:00

abstract：:Renal insufficiency is a frequent cancer-associated problem affecting more than half of all cancer patients at the time of diagnosis. To minimize nephrotoxic effects the dosage of anticancer drugs are reduced in these patients, leading to sub-optimal treatment efficacy. Despite the severity of this cancer-associated p...

journal_title：Oncoimmunology

authors： Cedervall J,Dragomir A,Saupe F,Zhang Y,Ärnlöv J,Larsson E,Dimberg A,Larsson A,Olsson AK

更新日期：2017-04-20 00:00:00

abstract：:The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase regression of cerv...

journal_title：Oncoimmunology

authors： Domingos-Pereira S,Hojeij R,Reggi E,Derré L,Chevalier MF,Romero P,Jichlinski P,Nardelli-Haefliger D

更新日期：2015-05-22 00:00:00

abstract：:There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III...

journal_title：Oncoimmunology

authors： Di Lullo G,Marcatti M,Heltai S,Brunetto E,Tresoldi C,Bondanza A,Bonini C,Ponzoni M,Tonon G,Ciceri F,Bordignon C,Protti MP

更新日期：2015-02-03 00:00:00

abstract：:Immunotherapy with oncolytic herpes simplex virus-1 therapy offers an innovative, targeted, less-toxic approach for treating brain tumors. However, a major obstacle in maximizing oncolytic virotherapy is a lack of comprehensive understanding of the underlying mechanisms that unfold in CNS tumors/associated microenviro...

journal_title：Oncoimmunology

authors： Bernstock JD,Vicario N,Rong L,Valdes PA,Choi BD,Chen JA,DiToro D,Osorio DS,Kachurak K,Gessler F,Johnston JM Jr,Atkinson TP,Whitley RJ,Bag AK,Gillespie GY,Markert JM,Maric D,Friedman GK

更新日期：2019-10-21 00:00:00

abstract：:Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of ch...

journal_title：Oncoimmunology

authors： van Dodewaard-de Jong JM,Santegoets SJ,van de Ven PM,Versluis J,Verheul HM,de Gruijl TD,Gerritsen WR,van den Eertwegh AJ

更新日期：2015-12-21 00:00:00

abstract：:Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological toler...

journal_title：Oncoimmunology

authors： Vacchelli E,Vitale I,Eggermont A,Fridman WH,Fučíková J,Cremer I,Galon J,Tartour E,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2013-10-01 00:00:00

abstract：:Immunomodulation is an important part of lenalidomide's mode of action. We analyzed the impact of lenalidomide on T cells from patients with multiple myeloma during lenalidomide therapy in vivo and in patients with lenalidomide-refractory disease in vitro Patients enrolled in the German Speaking Myeloma Multicenter Gr...

journal_title：Oncoimmunology

authors： Krämer I,Engelhardt M,Fichtner S,Neuber B,Medenhoff S,Bertsch U,Hillengass J,Raab MS,Hose D,Ho AD,Goldschmidt H,Hundemer M

更新日期：2016-02-18 00:00:00

abstract：:A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid ...

journal_title：Oncoimmunology

authors： Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

更新日期：2013-11-01 00:00:00

abstract：:We have developed a recombinant adenovirus vaccine encoding dopachrome tautomerase (rHuAd5-hDCT) that produces robust DCT-specific immunity, but only provides modest suppression of murine melanoma. In the current study, an agonist antibody against 4-1BB was shown to enhance rHuAd5-hDCT efficacy and evoke tumor regress...

journal_title：Oncoimmunology

authors： McGray AJ,Bernard D,Hallett R,Kelly R,Jha M,Gregory C,Bassett JD,Hassell JA,Pare G,Wan Y,Bramson JL

更新日期：2012-07-01 00:00:00

abstract：:The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small fraction of patients, underlining urgent need for improvement. We pr...

journal_title：Oncoimmunology

authors： Ekiz HA,Lai SA,Gundlapalli H,Haroun F,Williams MA,Welm AL

更新日期：2018-07-11 00:00:00

abstract：:Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells ...

journal_title：Oncoimmunology

authors： Davenport AJ,Jenkins MR,Ritchie DS,Prince HM,Trapani JA,Kershaw MH,Darcy PK,Neeson PJ

更新日期：2015-06-01 00:00:00

abstract：:Surgical resection of the primary tumor provides the best chance of cure for patients with colorectal carcinoma (CRC). However, bacterial translocation during intestinal surgery has been correlated with poor long-term oncological outcome. Therefore, we investigated the influence of bacterial contamination during colon...

journal_title：Oncoimmunology

authors： Grewal S,Korthouwer R,Bögels M,Braster R,Heemskerk N,Budding AE,Pouw SM,van Horssen J,Ankersmit M,Meijerink J,van den Tol P,Oosterling S,Bonjer J,Gül N,van Egmond M

更新日期：2018-07-26 00:00:00

abstract：:Human γδ T cells possess broad antitumor reactivity and are involved in the control of viral infections. We have recently described multifunctional γδ T cells induced by cytomegalovirus after allogenic stem cell transplantation, placing γδ T cells and their receptors in the spotlight for the development of novel antic...

journal_title：Oncoimmunology

authors： Scheper W,Gründer C,Kuball J

更新日期：2013-05-01 00:00:00

abstract：:Recent studies of human pancreatic cancer challenge the mouse model-derived notion that the pancreas is a site of immune privilege. A heavy infiltration of CD8+ T cells expressing programmed cell death 1 (PD-1) and smaller numbers of myeloid cells and regulatory T cells provides rationale for the clinical evaluation o...

journal_title：Oncoimmunology

authors： Pillarisetty VG

更新日期：2014-08-03 00:00:00

abstract：:Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a significant correlation b...

journal_title：Oncoimmunology

authors： Pan Y,Fei Q,Xiong P,Yang J,Zhang Z,Lin X,Pan M,Lu F,Huang H

更新日期：2019-03-01 00:00:00

abstract：:We have previously shown that the development of a major histocompatibility complex class I (MHC-I)-deficient tumor was favored in protein kinase C-θ knockout (PKC-θ-/-) mice compared to that occurring in wild-type mice. This phenomenon was associated with scarce recruitment of natural killer (NK) cells to the tumor s...

journal_title：Oncoimmunology

authors： Comet NR,Aguiló JI,Rathoré MG,Catalán E,Garaude J,Uzé G,Naval J,Pardo J,Villalba M,Anel A

更新日期：2014-11-14 00:00:00

abstract：:Oncolytic virotherapy is an emergent promising therapeutic approach for the treatment of cancer. We have constructed a vaccinia virus (WR strain) deleted for thymidine kinase (TK) and ribonucleotide reductase (RR) genes that expressed the fusion suicide gene FCU1 derived from the yeast cytosine deaminase and uracil ph...

journal_title：Oncoimmunology

authors： Fend L,Remy-Ziller C,Foloppe J,Kempf J,Cochin S,Barraud L,Accart N,Erbs P,Fournel S,Préville X

更新日期：2015-10-06 00:00:00

abstract：:Although high levels of tumor-infiltrating lymphocytes (TILs) generally correlate with good prognosis in high-grade serous ovarian cancer (HGSC) patients, little is known about the phenotype or specificity of these cells. We have recently demonstrated that TIL expressing the intra-epithelial lymphocyte marker CD103 (o...

journal_title：Oncoimmunology

authors： Webb JR,Milne K,Nelson BH

更新日期：2014-01-10 00:00:00

abstract：:Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytot...

journal_title：Oncoimmunology

authors： Adamopoulou E,Naumann U

更新日期：2013-08-01 00:00:00

abstract：:The metabolic gene isocitrate dehydrogenase 1 (IDH1) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-...

journal_title：Oncoimmunology

authors： Richardson LG,Nieman LT,Stemmer-Rachamimov AO,Zheng XS,Stafford K,Nagashima H,Miller JJ,Kiyokawa J,Ting DT,Wakimoto H,Cahill DP,Choi BD,Curry WT

更新日期：2020-08-20 00:00:00

abstract：:Purpose: Tumor development has been closely linked to tumor microenvironment, particularly in terms of myeloid-derived suppressive cells (MDSCs), a heterogeneous population of immature myeloid cells that protect tumors from elimination by immune cells. Approaches aimed at blocking MDSC accumulation could improve cance...

journal_title：Oncoimmunology

authors： Qin G,Lian J,Huang L,Zhao Q,Liu S,Zhang Z,Chen X,Yue D,Li L,Li F,Wang L,Umansky V,Zhang B,Yang S,Zhang Y

更新日期：2018-03-13 00:00:00

abstract：:Vaccines in combination with chemotherapy have been shown to be safe in different tumor types. We investigated the immunological activity of the TroVax® vaccine in combination with pemetrexed-cisplatin chemotherapy in malignant pleural mesothelioma (MPM). In this first line, open-label, single-arm, phase 2 study, pati...

journal_title：Oncoimmunology

authors： Lester JF,Casbard AC,Al-Taei S,Harrop R,Katona L,Attanoos RL,Tabi Z,Griffiths GO

更新日期：2018-09-07 00:00:00

abstract：:In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or benefi...

journal_title：Oncoimmunology

authors： Koristka S,Cartellieri M,Arndt C,Feldmann A,Seliger B,Ehninger G,Bachmann MP

更新日期：2015-01-23 00:00:00

abstract：:An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activa...

journal_title：Oncoimmunology

authors： Vacchelli E,Pol J,Bloy N,Eggermont A,Cremer I,Fridman WH,Galon J,Marabelle A,Kohrt H,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2015-02-03 00:00:00

abstract：:Monoclonal antibodies (mAb) induce tumor regression through antibody-dependant cellular cytotoxicity (ADCC). We recently showed that an agonistic anti-CD137 mAb stimulates natural killer (NK) cells which have been activated by a tumor-specific mAb, resulting in increased ADCC against cancer cells. ...

journal_title：Oncoimmunology

authors： Houot R,Kohrt H,Levy R

更新日期：2012-09-01 00:00:00

abstract：:Naïve T cells activated by antigen-presenting cells (APC) can be differentiated into at least four major types of T-helper (T(H)) cells: T(H)1, T(H)2, T(H)17 and inducible regulatory T cells (iTreg) based on their unique cytokine production profiles and characteristic functions.(1) T(H)1 produce interferon-γ (IFNγ) an...

journal_title：Oncoimmunology

authors： Pan F,Barbi J,Pardoll DM

更新日期：2012-07-01 00:00:00